Think Talk Treat, an Impactful Approach for Providers and Patients With Migraine: Bert B. Vargas, MD, FAHS, FAAN

WATCH TIME: 4 minutes

“What I love about Think Talk Treat Migraine is the fact that it is completely disease specific. It has nothing to do with any one particular medication or any one particular treatment and it has everything to do with addressing unmet needs in migraine care, or clinical care gaps, as we like to call it.”

Patients who experience migraine symptoms including sensitivity to light and/or nausea in combination with each other are often misdiagnosed with headache instead of migraine. Recently, Eli Lilly and Company created a program called “Think Talk Treat Migraine” to increase awareness and offer providers and patients the information needed to migraine diagnosis and care. In the previous prospective, web-based survey of people in the US with migraine, findings revealed that nearly half (45.5%) of respondents have hesitated to consult their physicians for migraine care.¹

Known as the OVERCOME study, investigators used the survey in order to assess the influence of sociodemographic, lifestyle, clinical characteristics, and patient reported outcomes on hesitating to consult for migraine care. Presented at the 2021 Virtual American Headache Society (AHS) 63rd Annual Scientific Meeting, June 3-6, investigators found that hesitating was most strongly associated with the patient reported outcomes (PROs) of lower mean Migraine-Specific Quality-of-Life Questionnaire-Role Function-Restrictive domain (MSQ 2.1 RFR; hesitating: 48.5; non-hestitating: 59.6scores and having at least moderate disability (56.2% hesitating; 35.9% not hesitating; P <.001).²

Recently, Bert B. Vargas, MD, FAHS, FAAN, associate vice president of neuroscience, US Medical Affairs, Eli Lilly, sat down in an interview with NeurologyLive® to further discuss the Think Talk Treat Migraine program and the way clinicians can use it to help their patients. He talked about how the program addresses the unmet needs in migraine care without focusing on specific medications. In addition, he also spoke about the most significant revelations from the OVERCOME study regarding the gaps in diagnosing and treating migraines. Furthermore, he explained how assessing impact differs from counting migraine days, and why it is crucial in determining preventive therapy suitability.

Learn more about the Think Talk Treat Migraine program here.

REFERENCES
1. Reed ML, Nicholson RA, Zagar AJ, et al. Important factors associated with hesitating to consult for migraine care: Results of the OVERCOME (US) study. Presented at 2021 AHS Annual Scientific Meeting; June 3-6. Abstract P12.
2. Lilly reveals critical barriers to optimal migraine care and insights from novel clinical and patient-centric real-world evidence, supporting Lilly's preventive and acute treatment portfolio at AHS 2021. News release. June 3, 2021. Accessed August 10, 2023. https://www.prnewswire.com/news-releases/lilly-reveals-critical-barriers-to-optimal-migraine-care-and-insights-from-novel-clinical-and-patient-centric-real-world-evidence-supporting-lillys-preventive-and-acute-treatment-portfolio-at-ahs-2021-301304727.html